Nationwide Research on the Rewilding of Kindergarten Yards
- Disease/Condition
- Microbial Colonization,Atopic Dermatitis,Asthma in Children,Allergy,Cognitive Change,Respiratory Infection,Nature, Human
- Drug/Device/Intervention
- Biodiversity
- Study type
- Interventional
- Intervention type
- biological
- Primary sponsor
- Natural Resources Institute Finland
- Location
- Helsinki,Tampere, Finland
- Phase
- N/A
- Start date
- May 01, 2024
- End date
- Aug 30, 2027
- Enrollment
- 320 participants
Skin Gammaproteobacteria
Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity
 in cities that is associated with altered commensal microbiota and a rising burden of
 immunological disorders among urban children.
 
 The investigators will estimate how rewilding of kindergarten yards affects commensal
 microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol
 levels, cognitive skills and plasma cytokine levels of children.
 
 Our specific aims are:
 
 To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and
 reduces infectious diseases and atopic or allergic symptoms.
 
 Assess whether the rewilding has positive effects on cognitive skills. Assess whether the
 rewilding changes cortisol and plasma cytokine levels. The investigators will recruit
 altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study
 (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological
 and blood samples (Task 1).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06390878
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06390878 through Pure Global AI's free database. This phase not specified trial is sponsored by Natural Resources Institute Finland and is currently Recruiting. The study focuses on Microbial Colonization,Atopic Dermatitis,Asthma in Children,Allergy,Cognitive Change,Respiratory Infection,Nature, Human. Target enrollment is 320 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.